RxSight, Inc. RXST

RXST Company Overview

RxSight, Inc. is a U.S.-based ophthalmic medical technology company focused on improving visual outcomes for patients undergoing cataract surgery. The company operates within the ophthalmology and medical device industries and is best known for developing the Light Adjustable Lens system, which enables postoperative adjustment of lens power after cataract surgery. RxSight’s primary revenue drivers include sales of its Light Adjustable Lens (LAL) implants, recurring procedure-related revenue, and sales or placements of its Light Delivery Device (LDD) systems used by surgeons to customize vision outcomes after implantation.

The company primarily serves ophthalmologists, ambulatory surgery centers, hospitals, and cataract surgery practices, with a concentration on premium intraocular lens procedures in the United States. RxSight’s strategic positioning is tied to its proprietary light-adjustable lens technology, which differentiates it from traditional fixed-power intraocular lenses by allowing postoperative refractive modifications. Founded in 1997, the company spent years developing and clinically validating its technology before receiving U.S. FDA approvals and commercializing its products more broadly during the 2020s. Public filings and investor disclosures indicate the company has focused heavily on clinical adoption, physician training, and expanding procedural utilization.